U.S. Retail Pharmacy Drug Sales Grew 5% to $190 billion
Retail pharmacy drug
sales in 13 key world markets in the 12 month period from July
2005 through to July 2006 grew 5% to reach
$377.39 billion, according to latest data from global healthcare
information company IMS
Health.
|
Retail Pharmacy Sales - 12 months: Jun'05 - Jul'06 |
|||
| Top 5 Drugs | Top 5 Companies | Top 5 Countries | |
| 1. Lipitor | Pfizer | USA |
$190.4B
|
| 2. Nexium | GSK | Japan (inc. hosp) |
$57.5B
|
| 3. Plavix | Novartis | Germany |
$27.0B
|
| 4. Seretide | AstraZeneca | France |
$24.6B
|
| 5. Zocor | Merck | UK |
$15.0B
|
| Source: IMS Health (October 2006) | |||
- North America posted a 5% sales growth at $203.52 billion in sales in the 12 months to July.
- U.S drug sales registered a 5% growth rate to hit $190 billion mark during the 12 month period.
- Sales in the top five European markets showed a 4% growth.
- Japan’s overall growth at constant exchange was 3%, with a market worth $57.47 billion in the 12 months to July 2006.
- Cardiovascular remains the largest therapeutic category with total sales of $75 billion with U.S. accounting for $37 billion.
- Lipitor from Pfizer continues to be the best selling drug with sales of over $11.58 billion, but at a reduced growth rate of 4.4%.
- Nexium has the largest growth rate of 16.2%.
- The top five drugs in terms of sales dollars are: 1. Lipitor, 2. Nexium, 3. Plavix, 4. Seretide 5. Zocor.
- The top five corporations by sales in the year are: 1. Pfizer, 2. GSK, 3. Novartis, 4. AstraZeneca 5. Merck.
Notes on the Data
Sales figures in these tables cover direct and indirect
pharmaceutical channel purchases (pharmacies plus hospitals and mail order
where indicated) from pharmaceutical wholesalers and manufacturers in 13
key international markets. Figures include prescription and certain
over-the-counter data, and represent manufacturer prices. These 13
countries account for over two thirds of the world market.
